NeoDocs Turned Your Phone Camera Into a Diagnostic Lab

There is a strange asymmetry in modern health. A ten-dollar band on your wrist will happily tell you your heart rate, your steps, your sleep stages, the second you wake up. But ask that same wrist what your kidneys are doing, or whether your blood sugar is quietly drifting, and it goes silent. For that, you still need a needle, a lab, a queue, and a report that lands two days later. Three engineers from IIT Bombay sat with that gap during the Covid lockdown and decided it was worth closing.

The company they built, NeoDocs, does something that sounds almost too simple when you say it out loud: it reads a health test with your phone's camera. You dip a paper card into a urine sample, open the NeoDocs app, take a photo of the card, and about thirty seconds later you have results referenced against lab-grade values. No phlebotomist. No fasting. No trip anywhere. The lab equipment is the phone already in your pocket.

01 / THE IDEAReading color the way a machine does

The science underneath is older than the startup. Urine test strips - the little cards that change color in the presence of glucose, protein, ketones and other markers - have been used in clinics for decades. What NeoDocs changed is who gets to read them. In a lab, a bench analyser shines light at the strip and measures the exact color response. NeoDocs replaced that expensive box with a computer-vision model. You photograph the card, the image goes to the cloud, and an algorithm reads the colors, corrects for your lighting and phone, and returns numbers.

That single move - from hardware reader to software reader - is the whole engine of the business. It means the thing a customer buys is a cheap piece of paper, and the intelligence lives in an app that only gets better as more cards get scanned. The company says its kidney test has been validated against gold-standard lab analysers, which is the part that has to be true for any of the rest to matter.

The hard problem is not the chemistry of the strip, which is well understood, but everything the human introduces. Two phones photograph the same card under two different kitchen lights and produce two different images. A camera's white balance shifts, a shadow falls across half the strip, the user holds the phone at an angle. A bench analyser never has to worry about any of that because it controls the light and the distance. NeoDocs has to correct for all of it in software before it can trust a single number, which is a big part of why the company spent so long getting the reading right before it started selling.

02 / THE STORYBorn in a lockdown, built in stealth

NeoDocs started in 2020, when Nikunj Malpani, Anurag Meena and Pratik Lodha - all IIT Bombay alumni - found themselves thinking about how little of personal health is actually measured. The lockdown had made everyone acutely aware of their own bodies and equally aware that there was no easy way to check on them. By 2021 the company was in Y Combinator's Summer batch. Then it did something a little unfashionable: it went quiet.

For roughly two years NeoDocs operated in what the founders describe as stealth, working on the harder, less glamorous problem of getting the readings right before making noise about them. In a startup culture that rewards loud launches, choosing accuracy first and attention later is a real decision. It paid off in a currency that matters in diagnostics: trust.

03 / THE PRODUCTDip, scan, done

The flagship is the NeoDocs Wellness Kit, a single urine test that reads up to eight to ten parameters at once - glucose, protein, ketones, pH, hydration, leukocytes, blood, nitrites. From there the line gets more specific. There is a uACR test for kidney health, a Kidney Care Kit built for people already on kidney or blood-pressure medication, and a UTI Care Kit. The experience across all of them is the same, and it is deliberately unclinical.

The design choice hiding inside that flow is the interesting part. NeoDocs made a medical test feel like using an app rather than visiting a clinic. For a category people avoid out of low-grade anxiety - nobody enjoys a lab visit - the interface is doing quiet therapeutic work. Cheap, fast and needle-free lowers the friction enough that people might actually test before something feels wrong, which is exactly when preventive testing is worth the most and exactly when nobody bothers.

04 / THE MARKETThe 90% who don't know

The number that explains NeoDocs' focus on kidneys is stark: roughly one in ten Indian adults has chronic kidney disease, and nine out of ten of them have no idea. India also has an enormous pre-diabetic population whose kidneys are quietly at risk. Kidney damage is a good target for a home test precisely because it is silent - by the time symptoms appear, a lot of damage is already done. A cheap uACR test you can do at home turns a screening that most people skip into something they might do routinely.

This is where NeoDocs sits apart from the rest of the Indian at-home diagnostics field. Companies like Orange Health, Healthians and the legacy pathology chains - Dr Lal PathLabs, SRL, Apollo Diagnostics - have all built home-collection services. But they are still labs; they send a phlebotomist to your door, take a sample, and process it centrally. NeoDocs removed the lab and the phlebotomist from the loop entirely. The competition is fighting over who owns the lab. NeoDocs is trying to own the thirty seconds between a sample and an answer.

05 / THE BUSINESSA one-dollar card and a smarter app

The model is direct-to-consumer. NeoDocs sells single-use test cards and tracking kits through its own site, Amazon and pharmacies like 1mg, and it runs a parallel channel through doctors who recommend the kits for at-home monitoring. The economics are the point: the physical product is cheap paper, and the margin and the moat live in the software layer that reads it. Every scan is training data; the reader gets better and cheaper to run over time while the card stays simple.

By early 2024 the company reported more than 200,000 test cards sold and working relationships with thousands of doctors across India - the kind of traction that turns a clever demo into a real business.

The doctor channel matters more than it first appears. A consumer buying a wellness kit off Amazon is one thing, but a physician handing a patient a card and saying "test yourself at home and send me the numbers" is a different kind of endorsement. It plugs NeoDocs into the existing trust between doctor and patient rather than asking a stranger to trust an app. For chronic conditions like kidney disease, where monitoring has to happen again and again, that repeat relationship is also the closest thing a diagnostics company has to recurring revenue.

06 / THE BACKERSWho bet on a urine test

In February 2024, after those two quiet years, NeoDocs raised a $2 million seed round - about Rs 16.6 crore - led by Omidyar Network India, with Y Combinator, 100Unicorns, Gemba Capital and Titan Capital joining. The angel list is the tell. It includes Kunal Shah of CRED, Varun Alagh of Mamaearth, a co-founder of 1mg, a boAt co-founder, and senior figures from Cloudnine and Narayana Health. That is a roster heavy on people who have built consumer trust and distribution at scale in India - which suggests the smart money thinks the hard part of home diagnostics is not the science, but getting millions of ordinary people to actually test.

The company has said it plans to use the funding to look beyond India. Whether the phone-as-lab model travels well across regulatory environments is the open question - but the underlying idea, that an expensive gatekept instrument can be replaced by a camera and a model, is not confined to one country or one kind of test.

07 / THE TAKEAWAYWhere it fits

There is also a broader shift NeoDocs is riding. A generation that grew up tracking workouts and sleep on their phones is more comfortable than any before it with turning their body into a stream of numbers. The instinct to measure is already there; what has been missing is a way to measure the things that actually predict disease without booking a lab appointment. If NeoDocs can keep the accuracy high and the price low, it is aiming at exactly that habit - the quiet, unglamorous act of checking in on yourself before anything is wrong.

NeoDocs is not trying to out-lab the labs. It is making a different bet: that the future of everyday health testing looks less like a pathology report and more like an app notification. It is early, the accuracy bar in diagnostics is unforgiving, and expanding abroad will test the model in new ways. But the core insight is clean enough to borrow into almost any field. Find the expensive, gatekept device that stands between people and information they need, then ask what a phone camera and a trained model could do in its place.